What is Ph+ CML?
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) is a type of cancer of the bone marrow and blood. In people with Ph+ CML, the bone marrow (the soft tissue inside bones where blood cells are made) produces too many white blood cells and these cells are often immature or damaged. About 4600 Americans were diagnosed with Ph+ CML in 2004, and the median age of diagnosis is 65.
A Closer Look at "Ph+ CML"
"Ph" is an abbreviation for "Philadelphia chromosome," the name given to the abnormal chromosome that can lead to the overproduction of white blood cells. The plus sign (+) means that your laboratory tests show your bone marrow and white blood cells contain the abnormal Philadelphia chromosome. "Chronic" means that it progresses slowly. "Myeloid" refers to the type of white blood cells that are affected. "Leukemia" tells you it is a cancer of the bone marrow and white blood cells.
So, when your doctor says you have Ph+ CML, it means that your bone marrow cells have an abnormal chromosome and your body is producing too many white blood cells. In addition to crowding out normal, healthy cells, these white blood cells often do not function normally.
How does Ph+ CML happen?
The soft tissue inside our bones, called the bone marrow, produces a type of cell called a stem cell. As stem cells mature, they can turn into platelets, red blood cells, or white blood cells. Ph+ CML happens because of changes in the genetic material of these stem cells.
Chromosomes are the parts of our cells that carry our DNA and genes—the things that give us our physical traits, such as blue eyes or brown hair, and that tell our body how to handle all the functions of life, including the process of making blood cells. Humans have 23 pairs of chromosomes. Ph+ CML happens when some genetic material from one chromosome (chromosome 9) switches position with some genetic material from another chromosome (chromosome 22).
The new genetic material on chromosome 22 is called BCR-ABL and leads to abnormalities in your body's process for making blood cells. When chromosome 22 has this abnormal BCR-ABL gene, scientists call it the Philadelphia chromosome. People with Ph+ CML have the BCR-ABL gene in their stem cells and white blood cells. The BCR-ABL gene produces a protein called Bcr-Abl. Scientists distinguish between the name of the gene and protein by how they are written.
The Bcr-Abl protein causes your bone marrow to produce more and more white blood cells and these white blood cells are often damaged. It acts like a switch that keeps your white blood cell production in the "on" position. Normally, your body would stop producing white bloods that weren't needed and damaged blood cells would die off, but the Bcr-Abl protein interferes with these processes. Instead, your bone marrow keeps making damaged white blood cells that, over time, crowd out healthy red blood cells and platelets.
Scientists do not know exactly why the genetic material switches between the 2 chromosomes and continue to search for causes of Ph+ CML. Although Ph+ CML involves genetic material, be assured that it is not inherited. The abnormal gene is not passed down from parent to child.
Signs and symptoms of Ph+ CML
Some common symptoms of Ph+ CML are:
Many people are diagnosed in the early stage of Ph+ CML and do not have any obvious signs and symptoms. Often Ph+ CML is discovered during a routine blood test when results show the person has an elevated white blood cell count.
The phases of Ph+ CML are based on the percentage of blast cells (immature white blood cells) as compared with other blood cells in the bone marrow:
Monitoring Your Ph+ CML
QT prolongation causes an irregular heartbeat, which may lead to sudden death.
Your doctor should check your heart with a test called an electrocardiogram (ECG):
TASIGNA® (nilotinib) Indications
TASIGNA is a prescription medicine used to treat adults with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The efficacy of TASIGNA is based on major molecular response and cytogenetic response rates. The study is on-going and more data will be needed to determine long-term outcomes.
TASIGNA is also used to treat chronic phase or accelerated phase Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in adults who are no longer benefiting from previous other treatments, including imatinib (GLEEVEC), or have taken other treatments, including imatinib (GLEEVEC) but cannot tolerate them. The efficacy of TASIGNA is based on hematologic response and cytogenetic response rates.
IMPORTANT SAFETY INFORMATION ABOUT TASIGNA® (nilotinib)
What is the most important information to know about prescription TASIGNA?
TASIGNA can cause a possible life-threatening heart problem called QT prolongation.
QT prolongation causes an irregular heartbeat, which may lead to sudden death.
Your doctor should check your heart with a test called an electrocardiogram (ECG):
You may lower your chances for having QT prolongation with TASIGNA if you:
Who should not take TASIGNA?
Do not take if you have:
Taking TASIGNA:
Before taking TASIGNA
Talk to your doctor or pharmacist about all other medication(s) you may be taking, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements, since they may affect how TASIGNA works and increase your chance of serious and life-threatening side effects.
Tell your doctor if:
Also tell your doctor if you are pregnant, breast-feeding, or lactose-intolerant. The TASIGNA capsules contain lactose. Most patients who have mild or moderate lactose intolerance can take TASIGNA.
Serious side effects
TASIGNA may cause serious side effects including:
Your doctor may do blood tests to check you for TLS
Call your doctor immediately if you experience any of these symptoms. Your doctor may change your dose. Your doctor may have you stop TASIGNA for some time or lower your dose if you have side effects with it.
Common side effects
Most patients experience side effects at some time. Some common side effects you may experience include:
Be sure to tell your doctor or pharmacist if you have any side effects during treatment with TASIGNA. You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
It is not known if TASIGNA is safe or effective in children.
Tell your doctor if you are pregnant or planning to become pregnant. TASIGNA may harm your unborn baby. If you are able to become pregnant, you should use effective birth control during treatment with TASIGNA. Talk to your doctor about the best birth control methods to prevent pregnancy while you are taking TASIGNA.
Tell your doctor if you are breast-feeding or plan to breast-feed. It is not known if TASIGNA passes into your breast milk. You and your doctor should decide if you will take TASIGNA or breast-feed. You should not do both.
If you take too much TASIGNA, call your doctor or poison control center right away.
Your doctor will check your heart, do regular blood tests, and take bone marrow samples during treatment with TASIGNA. These are done to check for side effects with TASIGNA and to see how well TASIGNA is working for you. Your doctor should check your blood to monitor the amount of blood cells (white blood cells, red blood cells, and platelets) during treatment. These should be checked every 2 weeks for the first 2 months and then monthly thereafter, or as considered necessary by your doctor.
Please see the full prescribing information including the Boxed WARNING, and the TASIGNA Medication Guide.